Marie-Hélène Pesant

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Clinically useful predictors of conversion to abnormal glucose tolerance in women with polycystic ovary syndrome

Marie-Hélène Pesant, Jean‐Patrice Baillargeon · Fertility and Sterility · 2010 · 27 citations

Medicine, Endocrinology, Gynecology +13

A 30-day toxicity study of inhaled fenitrothion in the albino rat

Charles B. Breckenridge, Marie-Hélène Pesant, Heather D. Durham et al. · Toxicology and Applied Pharmacology · 1982 · 22 citations

Pharmacy, Pharmacology, Toxicology +15

The Obesity-Fertility Protocol: a randomized controlled trial assessing clinical outcomes and costs of a transferable interdisciplinary lifestyle intervention, before and during pregnancy, in obese infertile women

Karine Duval, Marie‐France Langlois, Belina Carranza‐Mamane et al. · BMC Obesity · 2015 · 22 citations · Full text

Medicine, Gynecology, Pharmacoeconomics +17